We confirmed this regulation in larger patient data sets (on the mRNA level), as Six1 expression significantly inversely correlates with RPL26 expression across multiple tumour types, including breast, colon, prostate, lung, cervical, gastric and renal cancer (Fig. 6d; Supplementary Fig. 16b–h)28, 39, 40, 41, 42, 43, 44, 45, 46. This evidence concerns the gene RPL26 and renal carcinoma.